Rhodotorula Mucilaginosa: Causes, Symptoms, and Treatment

Rhodotorula mucilaginosa is a pink-pigmented yeast found widely in nature that occasionally causes serious infections in people with weakened immune systems or indwelling medical devices like central venous catheters. For healthy individuals, the yeast is essentially harmless and commonly encountered on skin, in dairy products, and in shower curtains. But in hospitals, it has earned a reputation as an emerging opportunistic pathogen, one that is inherently resistant to several of the most commonly used antifungal drugs and increasingly recognized as a cause of bloodstream infections in vulnerable patients.

What Rhodotorula Mucilaginosa Actually Is

Rhodotorula mucilaginosa belongs to a group of basidiomycete yeasts, meaning it sits on the same broad branch of the fungal family tree as mushrooms rather than the branch that includes Candida and other more familiar disease-causing yeasts. When grown on laboratory plates, it produces distinctive mucous, smooth-surfaced colonies that range from salmon-pink to deep orange-red. Under the microscope, the cells are oval or round and reproduce by budding, without forming the spore structures seen in many other fungi.¹ That distinctive pigmentation comes from carotenoids, the same family of pigments that make carrots orange and tomatoes red, and it helps the yeast tolerate ultraviolet light and oxidative stress in its natural environment.

Taxonomically, the genus Rhodotorula has been reshuffled more than once. Molecular studies revealed that the old genus was polyphyletic, meaning the species lumped together under the name were not all closely related. A revision based on multi-gene analysis redrew the boundaries, emending Rhodotorula to include both asexual and sexual forms based on genuine evolutionary relationships.² For clinicians, the practical takeaway is that accurate species-level identification matters, because different Rhodotorula species can behave differently in terms of drug resistance and virulence.

Who Gets Rhodotorula Infections and Why

The overwhelming majority of Rhodotorula mucilaginosa infections occur in people whose immune defenses are compromised. Patients with blood cancers, those who have undergone organ or stem cell transplants, people with HIV/AIDS, and individuals on long-term immunosuppressive medications like high-dose steroids are all at elevated risk. In a study at a tertiary care hospital, the two most common predisposing factors were prolonged hospital stays of more than a month and prolonged use of broad-spectrum antibiotics for more than a month.³ Long antibiotic courses can wipe out competing bacteria and give yeasts room to proliferate.

Central venous catheters are a major gateway. These long-term intravenous lines sit directly in the bloodstream, and if a yeast manages to colonize the catheter surface, it has a direct route into the blood. Rhodotorula mucilaginosa is especially good at forming biofilms on plastic surfaces, which helps it cling to catheters and resist the body’s defenses. Clinical isolates of R. mucilaginosa actually form stronger biofilms than environmental isolates of the same species, suggesting that the strains causing human disease may be selected for this trait.⁴

There is another, less obvious risk factor: the antifungal drugs a patient is already taking. A review of all reported Rhodotorula infections after stem cell transplantation found that every patient had been receiving fluconazole or an echinocandin for antifungal prophylaxis before the Rhodotorula infection appeared.⁵ Because R. mucilaginosa is naturally resistant to both drug classes, giving them to a patient eliminates competing fungi while leaving Rhodotorula unharmed, essentially clearing the field for it.

How Rhodotorula Mucilaginosa Establishes Infections

Compared to aggressive fungal pathogens like Aspergillus, R. mucilaginosa is not a powerfully virulent organism. It relies more on opportunity than on an arsenal of tissue-destroying enzymes. Its main virulence tools are its ability to adhere to surfaces, form biofilms, and resist commonly used antifungal drugs.

Biofilm formation is central to how it causes catheter-related infections. Once attached to a plastic surface, R. mucilaginosa builds a complex community embedded in an extracellular matrix made up of proteins, polysaccharides, and even extracellular DNA and RNA. This matrix acts as a shield, protecting the yeast cells from the immune system and from antifungal drugs that might otherwise kill free-floating cells.⁶ The biofilm essentially turns the catheter into a reservoir from which yeast cells can continuously shed into the bloodstream, sustaining an infection that will not resolve until the catheter is removed.

Types of Infection and Their Symptoms

Rhodotorula mucilaginosa can cause several types of infection, though bloodstream infection (fungemia) is by far the most common. A systematic review cataloging Rhodotorula infections in humans found that the most frequent were bloodstream infections, central nervous system infections, eye infections, and peritonitis in patients on peritoneal dialysis. The pattern of who gets which type differed: bloodstream infections were more common in cancer patients with central venous catheters, while central nervous system infections were more common in patients with AIDS. Death rates also varied, with central nervous system infections carrying the highest mortality.⁷

Bloodstream Infections

Fungemia is the bread and butter of Rhodotorula disease. The typical presentation is a hospitalized patient with a central venous catheter who develops a new fever that does not respond to antibacterial antibiotics. In one case, an immunocompetent patient with a central line developed a fever of 38.4°C along with a rapid heart rate and elevated breathing rate; blood cultures drawn from both the catheter and a peripheral vein grew yeast, with the catheter cultures turning positive hours earlier than the peripheral ones, confirming the catheter as the source.⁸

Not all cases involve catheters, though. An 81-year-old man with chronic lung disease and rheumatoid arthritis developed Rhodotorula fungemia without ever having had a central venous catheter implanted. He presented with shortness of breath and fever, and yeast was eventually identified in blood cultures by its characteristic salmon-pink colonies.⁹ Cases like this are less common but serve as a reminder that severely debilitated or immunosuppressed patients can develop Rhodotorula bloodstream infections through other routes, possibly including the gut or the respiratory tract.

Neonates in intensive care are another vulnerable group. In one outbreak, four premature infants with indwelling vascular catheters developed signs of sepsis over a 19-day period. Blood cultures confirmed R. mucilaginosa, and all four recovered after treatment with amphotericin B.¹⁰

Other Sites of Infection

Beyond the bloodstream, Rhodotorula can infect the eyes (endophthalmitis or keratitis), the lining of the brain and spinal cord (meningitis, primarily in AIDS patients), and the peritoneum in people undergoing continuous ambulatory peritoneal dialysis. Eye infections are especially concerning because they can lead to permanent vision loss if not treated promptly. Peritonitis in dialysis patients usually occurs when the yeast colonizes the dialysis catheter, and treatment often requires removing the catheter in addition to antifungal therapy. Skin and soft tissue infections are rare and tend to occur in patients with severely compromised immunity.

How It Is Diagnosed

Diagnosing a Rhodotorula infection starts with growing the organism from a clinical specimen, most often blood. In the microbiology lab, the yeast’s salmon-pink to coral-colored colonies on standard agar are a useful visual clue, though they can be initially mistaken for pigmented Candida species or other yeasts.

Getting the species identification right matters for treatment decisions, because drug resistance patterns differ among Rhodotorula species. Traditional biochemical identification systems get the job done in most cases but are not always accurate for less common yeasts. Newer methods like MALDI-TOF mass spectrometry, which identifies organisms by their protein fingerprint, have proven highly reliable for Rhodotorula, matching the accuracy of DNA sequencing in about 94% of cases.¹¹ DNA-based methods, particularly sequencing of the ribosomal ITS region, serve as the gold standard when there is any doubt.¹²

One practical concern is that clinicians may initially assume a yeast in the blood is Candida and start empirical treatment with fluconazole or an echinocandin, both of which are first-line therapies for candidemia. For Rhodotorula, this is the wrong call, because the yeast is resistant to both. Recognizing Rhodotorula early enough to switch therapy matters for outcomes.

Treatment and the Drug Resistance Problem

The defining challenge of treating Rhodotorula mucilaginosa is its intrinsic resistance to two of the most widely used classes of antifungal drugs. Fluconazole, the workhorse azole antifungal used against Candida, is essentially useless against Rhodotorula, with minimum inhibitory concentrations well above clinically achievable blood levels.¹³ Echinocandins like caspofungin and micafungin, another frontline class for invasive yeast infections, are similarly ineffective. In one laboratory study, every Rhodotorula strain tested was resistant to caspofungin, and roughly 95% were resistant to fluconazole.¹⁴

Amphotericin B is the drug that works. It consistently shows excellent activity against Rhodotorula species, and it is the treatment of choice for serious infections. Flucytosine, an older antifungal sometimes used in combination therapy, also has good in vitro activity.¹³ Among the newer azoles, posaconazole has the lowest minimum inhibitory concentrations, suggesting it could play a role in step-down therapy after initial treatment with amphotericin B.¹⁵ In the case of the 81-year-old man without a catheter mentioned earlier, doctors initially started micafungin but saw no improvement. Once the lab identified the yeast as R. mucilaginosa and they switched to liposomal amphotericin B, blood cultures cleared and the fever resolved.⁹

For catheter-related infections, removing the catheter is just as important as choosing the right drug. Reviews of reported fungemia cases consistently find that treatment involves amphotericin B combined with catheter removal in patients who have central venous lines.¹⁶ Leaving the catheter in place allows the biofilm to persist as a continuous source of yeast entering the blood, making cure unlikely with drugs alone.

Hospital Outbreaks and Emerging Resistance

R. mucilaginosa is not just a sporadic opportunistic infection. It can cause outbreaks, particularly in intensive care units. The neonatal ICU outbreak described earlier involved four infants over a short period, suggesting person-to-person or environmental transmission. More concerning is evidence from molecular epidemiology studies in China, which tracked an epidemic cluster of R. mucilaginosa persisting across multiple geographic regions. Molecular data indicated possible clonal transmission of strains that were resistant to echinocandins, azoles, and flucytosine, making them effectively pan-resistant to most available antifungals.¹⁷

The emergence of flucytosine resistance is particularly worrying because it narrows the treatment options even further. If a strain is resistant to azoles, echinocandins, and flucytosine, amphotericin B becomes essentially the only remaining option. And while amphotericin B is effective, it comes with significant side effects including kidney toxicity, making it a drug clinicians prefer to use judiciously rather than as the only tool in the box.

Infection control measures in hospitals mirror those used for other healthcare-associated fungal infections: strict hand hygiene, careful catheter insertion and maintenance protocols, and prompt removal of central lines when they are no longer needed. Environmental cleaning matters too, because Rhodotorula can survive on surfaces and in water systems.

Why a Healthy Person Probably Does Not Need to Worry

If you are reading this with a functioning immune system and no central venous catheter, R. mucilaginosa is overwhelmingly unlikely to cause you any harm. The yeast is part of the normal environmental microbiota. It has been isolated from air, soil, ocean water, milk, fruit juice, and bathroom surfaces. Many people carry it transiently on their skin or in their mouths without any consequences. It is only when the immune system is severely compromised, or when a foreign body like a catheter provides a direct entry point to the bloodstream, that R. mucilaginosa shifts from harmless bystander to pathogen. Even in immunocompromised patients, it remains a relatively uncommon cause of fungemia compared to Candida species.

The Industrial Side of Rhodotorula Mucilaginosa

The same yeast that occasionally causes hospital infections has attracted considerable interest from biotechnologists. R. mucilaginosa naturally produces carotenoid pigments, lipids, and enzymes, all of which have commercial value. Researchers have explored using it to produce natural food colorants, antioxidant supplements, and even feedstock for biodiesel production, with the advantage that the yeast can be grown on cheap agricultural waste materials like waste glycerol and potato processing wastewater.¹⁸ One study found that R. mucilaginosa grown on waste glycerol and potato wastewater accumulated roughly 15 grams of lipid per 100 grams of dry biomass while simultaneously producing carotenoids.¹⁹

In aquaculture and animal nutrition, R. mucilaginosa is being studied as a dietary supplement. Adding it to the diet of red claw crayfish significantly boosted growth rates and enhanced antioxidant and immune function compared to unsupplemented controls.²⁰ In gilthead sea bream, dietary supplementation did not improve growth but appeared to influence lipid metabolism and gut health, with enrichment of beneficial gut bacteria.²¹ These applications are still in the research phase, but they highlight that the organism’s relationship with animals is not purely adversarial.

Cleaning Up Heavy Metals

One of the more surprising chapters in the R. mucilaginosa story is its potential role in environmental cleanup. The yeast has a strong ability to tolerate and accumulate heavy metal ions, making it a candidate for bioremediation of contaminated water and soil.²² A study isolating a pigmented strain from the environment found it could grow in the presence of mercury concentrations as high as 80 milligrams per liter and bind up to about 70 milligrams of mercury per gram of yeast biomass. Carboxyl groups on the cell surface did most of the heavy lifting in grabbing mercury ions, followed by amino, hydroxyl, and phosphate groups.²³

The practical appeal is that biological remediation using a yeast like this could be cheaper and more environmentally friendly than chemical treatments for metal-contaminated water. Dead yeast cells actually bound slightly more mercury than living ones, which opens the possibility of using inactivated biomass as a sorbent material, sidestepping any biosafety concerns about releasing a living organism into the environment. Whether this scales up from the lab bench to real-world cleanup remains an open question, but the chemistry is promising.